Anti-spasmodic Drugs Market 2027 By Drugs, Route of Administration, Distribution Channel, and Geography | The Insight Partners

Anti-spasmodic Drugs Market Forecast to 2027 - COVID-19 Impact and Global Analysis By Drugs (Dicyclomine Hydrochloride, Loperamide Hydrochloride, Others); Route of Administration (Irritable Bowel Syndrome, Stomach Cramps, Others); Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy), and Geography

Report Code: TIPRE00013979 | No. of Pages: 150 | Category: Pharmaceuticals | Status: Upcoming
Covid
MARKET INTRODUCTION

Anti-spasmodic drugs consist of a wide range of medications used to treat medical symptoms that involves contraction and relaxation of muscles. For instance, medical symptoms include overactive bladder, muscle spasms, breathing problems, diarrhea, gastrointestinal cramps, and movement disorders. The drug can be taken through an oral and injectable administration route and is available as branded and generic medicine.

MARKET DYNAMICS

The anti-spasmodic drugs market is expected to grow due to key driving factors, such as the increasing pharmaceutical production, increasing incidences of bowel syndrome, and growing geriatric population. The market is expected to have growth opportunities due to increasing market consolidations and emerging startups in the developing regions.

MARKET SCOPE

The "Anti-spasmodic Drugs Market Analysis to 2027" is a specialized and in-depth study of the healthcare industry with a special focus on the global market trend analysis. The report aims to provide an overview of anti-spasmodic drugs market with detailed market segmentation by drug, route of administration, distribution channel. The anti-spasmodic drugs market is expected to witness high growth during the forecast period. The report provides key statistics on the market status of the leading players in anti-spasmodic drugs market and offers key trends and opportunities in the market.

MARKET SEGMENTATION

The anti-spasmodic drugs market is segmented on the basis of drug, route of administration, distribution channel. Based on drug, the market is segmented as dicyclomine hydrochloride, loperamide hydrochloride, and others. Based on route of administration, the market is classified as irritable bowel syndrome, stomach cramps, and others And based on distribution channel, the market is divided as hospital pharmacy, online pharmacy, and retail pharmacy.

REGIONAL FRAMEWORK

The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides overview and forecast of the anti-spasmodic drugs market based on various segments. It also provides market size and forecast estimates from year 2019 to 2027 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South & Central America. The anti-spasmodic drugs market by each region is later sub-segmented by respective countries and segments. The report covers analysis and forecast of 18 countries globally along with current trend and opportunities prevailing in the region.

The report analyzes factors affecting anti-spasmodic drugs market from both demand and supply side and further evaluates market dynamics affecting the market during forecast period i.e., drivers, restraints, opportunities, and future trend. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA and South & Central America after evaluating political, economic, social and technological factors effecting the Anti-spasmodic drugs market in these regions.



Get more information on this report :

MARKET PLAYERS


The report covers key developments in the anti-spasmodic drugs market as organic and inorganic growth strategies. Various companies are focusing on organic growth strategies such as product launches, product approvals and others such as patents and events. Inorganic growth strategies witnessed in the market were acquisitions, and partnership & collaborations. These activities have paved way for expansion of business and customer base of market players. The market players from anti-spasmodic drugs market are anticipated to have lucrative growth opportunities in the future with the rising demand for sleep monitoring devices in the global market. Below mentioned is the list of few companies engaged in the anti-spasmodic drugs market.

The report also includes the profiles of key players in anti-spasmodic drugs market along with their SWOT analysis and market strategies. In addition, the report focuses on leading industry players with information such as company profiles, components and services offered, financial information of last 3 years, key development in past five years.

  •  AbbVie Inc. (Allergan)
  •  Cadila Pharmaceuticals
  •  Abbott
  •  Mylan N.V.
  •  Fresenius Kabi
  •  SunGen Pharma LLC
  •  Nexus Pharmaceuticals
  •  Pfizer Inc.
  •  Teva Pharmaceutical Industries Ltd.
  •  Hikma Pharmaceuticals

The Insight Partner's dedicated research and analysis team consists of experienced professionals with advanced statistical expertise and offers various customization options in the existing study.


Get more information on this report :

TABLE OF CONTENTS

1. INTRODUCTION
1.1. SCOPE OF THE STUDY
1.2. THE INSIGHT PARTNERS RESEARCH REPORT GUIDANCE
1.3. MARKET SEGMENTATION
1.3.1 Anti-spasmodic Drugs Market - By Drugs
1.3.2 Anti-spasmodic Drugs Market - By Route of Administration
1.3.3 Anti-spasmodic Drugs Market - By Distribution Channel
1.3.4 Anti-spasmodic Drugs Market - By Region
1.3.4.1 By Country
2. KEY TAKEAWAYS
3. RESEARCH METHODOLOGY
4. ANTI-SPASMODIC DRUGS MARKET LANDSCAPE
4.1. OVERVIEW
4.2. PEST ANALYSIS
4.2.1 North America - Pest Analysis
4.2.2 Europe - Pest Analysis
4.2.3 Asia-Pacific - Pest Analysis
4.2.4 Middle East and Africa - Pest Analysis
4.2.5 South and Central America - Pest Analysis
4.3. EXPERT OPINIONS
5. ANTI-SPASMODIC DRUGS MARKET - KEY MARKET DYNAMICS
5.1. KEY MARKET DRIVERS
5.2. KEY MARKET RESTRAINTS
5.3. KEY MARKET OPPORTUNITIES
5.4. FUTURE TRENDS
5.5. IMPACT ANALYSIS OF DRIVERS AND RESTRAINTS
6. ANTI-SPASMODIC DRUGS MARKET - GLOBAL MARKET ANALYSIS
6.1. ANTI-SPASMODIC DRUGS - GLOBAL MARKET OVERVIEW
6.2. ANTI-SPASMODIC DRUGS - GLOBAL MARKET AND FORECAST TO 2027
6.3. MARKET POSITIONING/MARKET SHARE
7. ANTI-SPASMODIC DRUGS MARKET - REVENUE AND FORECASTS TO 2027 - DRUGS
7.1. OVERVIEW
7.2. DRUGS MARKET FORECASTS AND ANALYSIS
7.3. DICYCLOMINE HYDROCHLORIDE
7.3.1. Overview
7.3.2. Dicyclomine Hydrochloride Market Forecast and Analysis
7.4. LOPERAMIDE HYDROCHLORIDE
7.4.1. Overview
7.4.2. Loperamide Hydrochloride Market Forecast and Analysis
7.5. OTHERS
7.5.1. Overview
7.5.2. Others Market Forecast and Analysis
8. ANTI-SPASMODIC DRUGS MARKET - REVENUE AND FORECASTS TO 2027 - ROUTE OF ADMINISTRATION
8.1. OVERVIEW
8.2. ROUTE OF ADMINISTRATION MARKET FORECASTS AND ANALYSIS
8.3. IRRITABLE BOWEL SYNDROME
8.3.1. Overview
8.3.2. Irritable Bowel Syndrome Market Forecast and Analysis
8.4. STOMACH CRAMPS
8.4.1. Overview
8.4.2. Stomach Cramps Market Forecast and Analysis
8.5. OTHERS
8.5.1. Overview
8.5.2. Others Market Forecast and Analysis
9. ANTI-SPASMODIC DRUGS MARKET - REVENUE AND FORECASTS TO 2027 - DISTRIBUTION CHANNEL
9.1. OVERVIEW
9.2. DISTRIBUTION CHANNEL MARKET FORECASTS AND ANALYSIS
9.3. HOSPITAL PHARMACY
9.3.1. Overview
9.3.2. Hospital Pharmacy Market Forecast and Analysis
9.4. ONLINE PHARMACY
9.4.1. Overview
9.4.2. Online Pharmacy Market Forecast and Analysis
9.5. RETAIL PHARMACY
9.5.1. Overview
9.5.2. Retail Pharmacy Market Forecast and Analysis
10. ANTI-SPASMODIC DRUGS MARKET REVENUE AND FORECASTS TO 2027 - GEOGRAPHICAL ANALYSIS
10.1. NORTH AMERICA
10.1.1 North America Anti-spasmodic Drugs Market Overview
10.1.2 North America Anti-spasmodic Drugs Market Forecasts and Analysis
10.1.3 North America Anti-spasmodic Drugs Market Forecasts and Analysis - By Drugs
10.1.4 North America Anti-spasmodic Drugs Market Forecasts and Analysis - By Route of Administration
10.1.5 North America Anti-spasmodic Drugs Market Forecasts and Analysis - By Distribution Channel
10.1.6 North America Anti-spasmodic Drugs Market Forecasts and Analysis - By Countries
10.1.6.1 United States Anti-spasmodic Drugs Market
10.1.6.1.1 United States Anti-spasmodic Drugs Market by Drugs
10.1.6.1.2 United States Anti-spasmodic Drugs Market by Route of Administration
10.1.6.1.3 United States Anti-spasmodic Drugs Market by Distribution Channel
10.1.6.2 Canada Anti-spasmodic Drugs Market
10.1.6.2.1 Canada Anti-spasmodic Drugs Market by Drugs
10.1.6.2.2 Canada Anti-spasmodic Drugs Market by Route of Administration
10.1.6.2.3 Canada Anti-spasmodic Drugs Market by Distribution Channel
10.1.6.3 Mexico Anti-spasmodic Drugs Market
10.1.6.3.1 Mexico Anti-spasmodic Drugs Market by Drugs
10.1.6.3.2 Mexico Anti-spasmodic Drugs Market by Route of Administration
10.1.6.3.3 Mexico Anti-spasmodic Drugs Market by Distribution Channel
10.2. EUROPE
10.2.1 Europe Anti-spasmodic Drugs Market Overview
10.2.2 Europe Anti-spasmodic Drugs Market Forecasts and Analysis
10.2.3 Europe Anti-spasmodic Drugs Market Forecasts and Analysis - By Drugs
10.2.4 Europe Anti-spasmodic Drugs Market Forecasts and Analysis - By Route of Administration
10.2.5 Europe Anti-spasmodic Drugs Market Forecasts and Analysis - By Distribution Channel
10.2.6 Europe Anti-spasmodic Drugs Market Forecasts and Analysis - By Countries
10.2.6.1 Germany Anti-spasmodic Drugs Market
10.2.6.1.1 Germany Anti-spasmodic Drugs Market by Drugs
10.2.6.1.2 Germany Anti-spasmodic Drugs Market by Route of Administration
10.2.6.1.3 Germany Anti-spasmodic Drugs Market by Distribution Channel
10.2.6.2 France Anti-spasmodic Drugs Market
10.2.6.2.1 France Anti-spasmodic Drugs Market by Drugs
10.2.6.2.2 France Anti-spasmodic Drugs Market by Route of Administration
10.2.6.2.3 France Anti-spasmodic Drugs Market by Distribution Channel
10.2.6.3 Italy Anti-spasmodic Drugs Market
10.2.6.3.1 Italy Anti-spasmodic Drugs Market by Drugs
10.2.6.3.2 Italy Anti-spasmodic Drugs Market by Route of Administration
10.2.6.3.3 Italy Anti-spasmodic Drugs Market by Distribution Channel
10.2.6.4 Spain Anti-spasmodic Drugs Market
10.2.6.4.1 Spain Anti-spasmodic Drugs Market by Drugs
10.2.6.4.2 Spain Anti-spasmodic Drugs Market by Route of Administration
10.2.6.4.3 Spain Anti-spasmodic Drugs Market by Distribution Channel
10.2.6.5 United Kingdom Anti-spasmodic Drugs Market
10.2.6.5.1 United Kingdom Anti-spasmodic Drugs Market by Drugs
10.2.6.5.2 United Kingdom Anti-spasmodic Drugs Market by Route of Administration
10.2.6.5.3 United Kingdom Anti-spasmodic Drugs Market by Distribution Channel
10.3. ASIA-PACIFIC
10.3.1 Asia-Pacific Anti-spasmodic Drugs Market Overview
10.3.2 Asia-Pacific Anti-spasmodic Drugs Market Forecasts and Analysis
10.3.3 Asia-Pacific Anti-spasmodic Drugs Market Forecasts and Analysis - By Drugs
10.3.4 Asia-Pacific Anti-spasmodic Drugs Market Forecasts and Analysis - By Route of Administration
10.3.5 Asia-Pacific Anti-spasmodic Drugs Market Forecasts and Analysis - By Distribution Channel
10.3.6 Asia-Pacific Anti-spasmodic Drugs Market Forecasts and Analysis - By Countries
10.3.6.1 Australia Anti-spasmodic Drugs Market
10.3.6.1.1 Australia Anti-spasmodic Drugs Market by Drugs
10.3.6.1.2 Australia Anti-spasmodic Drugs Market by Route of Administration
10.3.6.1.3 Australia Anti-spasmodic Drugs Market by Distribution Channel
10.3.6.2 China Anti-spasmodic Drugs Market
10.3.6.2.1 China Anti-spasmodic Drugs Market by Drugs
10.3.6.2.2 China Anti-spasmodic Drugs Market by Route of Administration
10.3.6.2.3 China Anti-spasmodic Drugs Market by Distribution Channel
10.3.6.3 India Anti-spasmodic Drugs Market
10.3.6.3.1 India Anti-spasmodic Drugs Market by Drugs
10.3.6.3.2 India Anti-spasmodic Drugs Market by Route of Administration
10.3.6.3.3 India Anti-spasmodic Drugs Market by Distribution Channel
10.3.6.4 Japan Anti-spasmodic Drugs Market
10.3.6.4.1 Japan Anti-spasmodic Drugs Market by Drugs
10.3.6.4.2 Japan Anti-spasmodic Drugs Market by Route of Administration
10.3.6.4.3 Japan Anti-spasmodic Drugs Market by Distribution Channel
10.3.6.5 South Korea Anti-spasmodic Drugs Market
10.3.6.5.1 South Korea Anti-spasmodic Drugs Market by Drugs
10.3.6.5.2 South Korea Anti-spasmodic Drugs Market by Route of Administration
10.3.6.5.3 South Korea Anti-spasmodic Drugs Market by Distribution Channel
10.4. MIDDLE EAST AND AFRICA
10.4.1 Middle East and Africa Anti-spasmodic Drugs Market Overview
10.4.2 Middle East and Africa Anti-spasmodic Drugs Market Forecasts and Analysis
10.4.3 Middle East and Africa Anti-spasmodic Drugs Market Forecasts and Analysis - By Drugs
10.4.4 Middle East and Africa Anti-spasmodic Drugs Market Forecasts and Analysis - By Route of Administration
10.4.5 Middle East and Africa Anti-spasmodic Drugs Market Forecasts and Analysis - By Distribution Channel
10.4.6 Middle East and Africa Anti-spasmodic Drugs Market Forecasts and Analysis - By Countries
10.4.6.1 South Africa Anti-spasmodic Drugs Market
10.4.6.1.1 South Africa Anti-spasmodic Drugs Market by Drugs
10.4.6.1.2 South Africa Anti-spasmodic Drugs Market by Route of Administration
10.4.6.1.3 South Africa Anti-spasmodic Drugs Market by Distribution Channel
10.4.6.2 Saudi Arabia Anti-spasmodic Drugs Market
10.4.6.2.1 Saudi Arabia Anti-spasmodic Drugs Market by Drugs
10.4.6.2.2 Saudi Arabia Anti-spasmodic Drugs Market by Route of Administration
10.4.6.2.3 Saudi Arabia Anti-spasmodic Drugs Market by Distribution Channel
10.4.6.3 U.A.E Anti-spasmodic Drugs Market
10.4.6.3.1 U.A.E Anti-spasmodic Drugs Market by Drugs
10.4.6.3.2 U.A.E Anti-spasmodic Drugs Market by Route of Administration
10.4.6.3.3 U.A.E Anti-spasmodic Drugs Market by Distribution Channel
10.5. SOUTH AND CENTRAL AMERICA
10.5.1 South and Central America Anti-spasmodic Drugs Market Overview
10.5.2 South and Central America Anti-spasmodic Drugs Market Forecasts and Analysis
10.5.3 South and Central America Anti-spasmodic Drugs Market Forecasts and Analysis - By Drugs
10.5.4 South and Central America Anti-spasmodic Drugs Market Forecasts and Analysis - By Route of Administration
10.5.5 South and Central America Anti-spasmodic Drugs Market Forecasts and Analysis - By Distribution Channel
10.5.6 South and Central America Anti-spasmodic Drugs Market Forecasts and Analysis - By Countries
10.5.6.1 Brazil Anti-spasmodic Drugs Market
10.5.6.1.1 Brazil Anti-spasmodic Drugs Market by Drugs
10.5.6.1.2 Brazil Anti-spasmodic Drugs Market by Route of Administration
10.5.6.1.3 Brazil Anti-spasmodic Drugs Market by Distribution Channel
10.5.6.2 Argentina Anti-spasmodic Drugs Market
10.5.6.2.1 Argentina Anti-spasmodic Drugs Market by Drugs
10.5.6.2.2 Argentina Anti-spasmodic Drugs Market by Route of Administration
10.5.6.2.3 Argentina Anti-spasmodic Drugs Market by Distribution Channel
11. IMPACT OF COVID-19 PANDEMIC ON GLOBAL ANTI-SPASMODIC DRUGS MARKET
11.1 North America
11.2 Europe
11.3 Asia-Pacific
11.4 Rest of the World
12. INDUSTRY LANDSCAPE
12.1. MERGERS AND ACQUISITIONS
12.2. AGREEMENTS, COLLABORATIONS AND JOINT VENTURES
12.3. NEW PRODUCT LAUNCHES
12.4. EXPANSIONS AND OTHER STRATEGIC DEVELOPMENTS
13. ANTI-SPASMODIC DRUGS MARKET, KEY COMPANY PROFILES
13.1. ABBVIE INC. (ALLERGAN)
13.1.1. Key Facts
13.1.2. Business Description
13.1.3. Products and Services
13.1.4. Financial Overview
13.1.5. SWOT Analysis
13.1.6. Key Developments
13.2. CADILA PHARMACEUTICALS
13.2.1. Key Facts
13.2.2. Business Description
13.2.3. Products and Services
13.2.4. Financial Overview
13.2.5. SWOT Analysis
13.2.6. Key Developments
13.3. ABBOTT
13.3.1. Key Facts
13.3.2. Business Description
13.3.3. Products and Services
13.3.4. Financial Overview
13.3.5. SWOT Analysis
13.3.6. Key Developments
13.4. MYLAN N.V.
13.4.1. Key Facts
13.4.2. Business Description
13.4.3. Products and Services
13.4.4. Financial Overview
13.4.5. SWOT Analysis
13.4.6. Key Developments
13.5. FRESENIUS KABI
13.5.1. Key Facts
13.5.2. Business Description
13.5.3. Products and Services
13.5.4. Financial Overview
13.5.5. SWOT Analysis
13.5.6. Key Developments
13.6. SUNGEN PHARMA LLC
13.6.1. Key Facts
13.6.2. Business Description
13.6.3. Products and Services
13.6.4. Financial Overview
13.6.5. SWOT Analysis
13.6.6. Key Developments
13.7. NEXUS PHARMACEUTICALS
13.7.1. Key Facts
13.7.2. Business Description
13.7.3. Products and Services
13.7.4. Financial Overview
13.7.5. SWOT Analysis
13.7.6. Key Developments
13.8. PFIZER INC.
13.8.1. Key Facts
13.8.2. Business Description
13.8.3. Products and Services
13.8.4. Financial Overview
13.8.5. SWOT Analysis
13.8.6. Key Developments
13.9. TEVA PHARMACEUTICAL INDUSTRIES LTD.
13.9.1. Key Facts
13.9.2. Business Description
13.9.3. Products and Services
13.9.4. Financial Overview
13.9.5. SWOT Analysis
13.9.6. Key Developments
13.10. HIKMA PHARMACEUTICALS
13.10.1. Key Facts
13.10.2. Business Description
13.10.3. Products and Services
13.10.4. Financial Overview
13.10.5. SWOT Analysis
13.10.6. Key Developments
14. APPENDIX
14.1. ABOUT THE INSIGHT PARTNERS
14.2. GLOSSARY OF TERMS
The List of Companies

1. AbbVie Inc. (Allergan)
2. Cadila Pharmaceuticals
3. Abbott
4. Mylan N.V.
5. Fresenius Kabi
6. SunGen Pharma LLC
7. Nexus Pharmaceuticals
8. Pfizer Inc.
9. Teva Pharmaceutical Industries Ltd.
10. Hikma Pharmaceuticals
TIPRE00013979
Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.

Pricing

Free

20%

customization on Pre-Booking